Connect with us

Technology

NeoImmuneTech’s New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology

Published

on

Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancerCorrelative analysis identified potentially predictive protein biomarkers associated with patients experiencing the most clinical benefits from combination treatment of NT-I7 and CPICombination of NT-I7 and oncolytic virus demonstrates clear survival improvement in preclinical glioblastoma results

ROCKVILLE, Md., June 3, 2024 /PRNewswire/ — NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced promising interim results of its major clinical trial NIT-110 of NT-I7 (efineptakin alfa), at the 2024 American Society of Clinical Oncology (ASCO) global meeting held in Chicago, from May 31 to June 4. The company also presented two additional posters at the conference.

NIT-110 is a foundational clinical trial for NT-I7 that aims to confirm the safety and efficacy of combining NT-I7 with pembrolizumab (Keytruda®) in solid tumors. The data presented at ASCO 2024 confirmed that the combination is safe and well-tolerated.

Key findings from NIT-110 include:

Pancreatic cancer – Data showed a median overall survival (mOS) of 11.1 months among the 48 pancreatic cancer patients included in the study. The mOS for pancreatic cancer patients who have received a second-line standard of care treatment is currently known to be 6.1 months[1]. This mOS improvement is particularly noteworthy considering that 93.75% of the patients are receiving the combination treatment as third-line or beyond.MSS colorectal cancer -The mOS for the 50 microsatellite-stable (MSS) colorectal cancer patients was 13.2 months. The mOS for the current standard of care treatment is 10.8 months[2].

These results underscore the improved efficacy of the NT-I7 and Keytruda combination over existing standard of care treatments.

A separate poster from trial NIT-110 revealed a correlative analysis identifying a potentially predictive biomarker. These biomarkers may help identify patient populations more likely to benefit clinically from the NT-I7 and Keytruda combination. NeoImmuneTech is committed to further biomarker validation to enhance clinical outcomes.

Additionally, a preclinical study presented at ASCO 2024 highlighted the combination of NT-I7 with an oncolytic virus (ZIKV) in a glioblastoma animal model. Results demonstrated a significant increase in tumor specific CD8 T cells in the tumor microenvironment, leading to improved survival rates. Furthermore, 80% of cases in the experimental group combining NT-I7 with immune checkpoint inhibitors resulted in complete tumor eradication. NT-I7 continues to show clinical benefits driven by T cell amplification when combined with immune therapies.

NeoImmuneTech’s CEO, Luke Oh, PhD, said: “We are very encouraged by the improved clinical efficacy over standard of care in pancreatic and colorectal cancer, a notoriously difficult to treat cancer. These findings confirm our promising preclinical data and open new pathways to further enhance clinical outcomes. We are actively discussing the next steps with Merck. The results presented at ASCO 2024 confirm our strategy to continue to develop NT-I7 in the larger and high-potential immuno-oncology market.”

Posters references:

Abstract #

Track

Poster board #

Title

2621 (Link)

Developmental Therapeutics -Immunotherapy

100

A Phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat MSS-CRC and PDAC gastrointestinal tumors

2563

(Link)

Developmental Therapeutics -Immunotherapy

42

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors

2043

(Link)

Central Nervous System Tumors

342

Expand and pull: a new treatment paradigm for glioblastoma using a long-acting recombinant interleukin-7 and oncolytic viral therapy

 

About Study NIT-110
NIT-110 is an open label Phase 2a clinical trial supported by Merck that aims to confirm the efficacy of combining NT-I7 with Keytruda in two solid tumors. Early results in 2022 had confirmed the efficacy of the combination in pancreatic cancer and MSS colorectal cancer patients, who are known to be unresponsive to immune checkpoint inhibitors alone. Consequently, 24 and 25 additional patients were recruited for each group, respectively, bringing the total to 48 pancreatic cancer patients and 50 MSS colorectal cancer patients currently undergoing clinical trials. Results presented at ASCO 2024 provide an updated analysis including the original and expansion cohorts.

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.

Forward-looking Statements

The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the “Company”) that are based on its beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond the Company’s control and are not a guarantee of future performance or developments. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of these documents. Accordingly, you should not place reliance on any forward-looking information or statements contained herein.

Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data. Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties and is subject to change based on various factors.

[1] Wang-Gillam et al. Lancet. 2016. doi:10.1016/S0140-6736(15)00986-1
[2] Prager et al. N Engl J Med. 2023. doi:10.1056/NEJMoa221496

 

View original content:https://www.prnewswire.com/news-releases/neoimmunetechs-new-data-at-asco-2024-highlights-enhanced-benefits-of-combining-nt-i7-with-checkpoint-inhibitors-cpi-in-immuno-oncology-302161746.html

SOURCE The NeoImmuneTech, Inc

Continue Reading

Technology

Victory Live Named Official Data and Analytics Provider of the Capital One Orange Bowl

Published

on

By

Partnership provides ticketing technology and analytics support ahead of the 2027 College Football Playoff Semifinal

ATLANTA, Oct. 19, 2026 /PRNewswire/ — Victory Live, a leader in ticketing technology and analytics, today announced a partnership with the Orange Bowl to serve as the Official Data and Analytics Provider of the Capital One Orange Bowl.

Under the agreement, Victory Live will provide ticketing data and analytics tools to support the Orange Bowl’s operational planning and ticketing strategies.

The Capital One Orange Bowl is scheduled to host a College Football Playoff Semifinal on Thursday, Jan. 14, 2027, at Hard Rock Stadium.

“The Orange Bowl has a proud history in college football and a lasting impact on South Florida,” said Sam Soni, founder and CEO of Victory Live. “We look forward to supporting the organization with technology and data insights to assist their ticketing operations. With a College Football Playoff Semifinal ahead, this is an exciting opportunity to work together on an event that means so much to fans and the community.”

About Victory Live

Founded in 2021 by Sam Soni, Victory Live is a technology platform specializing in sports and entertainment event management, ticketing software, data insights, and multi-channel distribution. Its end-to-end solution, Victory Live One, helps manage millions of tickets for live event rightsholders and ticket sellers across sports, concerts, and theatre. Victory Live’s marketplace is the industry leader in B2B ticket distribution and connectivity solutions. Learn more at www.victorylive.com. 

Press Contact:

Eric Nemeth
nemeth@ericpr.com
www.victorylive.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/victory-live-named-official-data-and-analytics-provider-of-the-capital-one-orange-bowl-302912840.html

SOURCE Victory Live

Continue Reading

Technology

Eastern Michigan University offers $4,000 scholarships to students who join marching band

Published

on

By

YPSILANTI, Mich., Oct. 19, 2026 /PRNewswire/ — Eastern Michigan University is offering eligible students a $4,000 scholarship to join the university’s Marching Band, giving students the opportunity to participate in one of EMU’s signature traditions while pursuing any academic major.

The scholarship provides $1,000 per year for four years and is available to all students who meet the marching band requirements. Students do not need to major in music to qualify.

“I’m thrilled that President Kelly and the executive leadership team have elected to pursue this opportunity at Eastern because it gives us an opportunity to attract more students and reward them for the countless hours they spend participating in a life-changing activity that they love,” said J. Nick Smith, associate director of bands and director of Athletic Bands at Eastern.

EMU’s Marching Band reflects the university’s broad academic community. Only about 40% of its members are music majors, while students in disciplines across the university make up the rest of the membership.

“As a two-time alum, I’m proud of our band and its continuous momentum over the years,” said EMU President Brendan Kelly. “EMU’s college experience is about finding and building community — that’s what our marching band is all about. I’m thrilled we can offer this scholarship to students who want to be a part of a movement they’ll remember and be proud of among people with shared interests for the rest of their lives.”

Known as the “Pride of the Peninsula,” EMU’s Marching Band has a 132-year history and provides students with opportunities to perform at athletic events and other university and community events. The ensemble also offers diverse musical and performance experiences, including collaborations with groups such as internationally known piano-rock duo and EMU alumni Drew & Kin and Grammy Award-winning artists such as The Temptations, featuring EMU alum Jawan M. Jackson, who joined the group in 2022.

Participation in the band also provides students with experiences that extend beyond the field.

“Students who participate with us develop deep ties to their education, lifelong friends, lessons in leadership, professionalism, time management, high expectations and advanced musicianship and marching skills,” said Smith. “We pride ourselves on providing our students life-changing experiences that develop their core being so that, upon graduation, they have a diverse set of skills that are immediately applicable to their careers.”

Students interested in joining the EMU Marching Band and applying for the scholarship should:

Apply to and be admitted to Eastern Michigan University: emich.edu/apply/Complete the marching band membership form: https://tiny.emich.edu/emumbAttend orientation and register for marching band.Receive the scholarship through their financial aid package once all requirements are completed.

The scholarship is available to students regardless of their intended major. For more information about the EMU Marching Band and scholarship opportunities, visit the band webpage. To view the band’s past performances, visit the band’s YouTube page.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eastern-michigan-university-offers-4-000-scholarships-to-students-who-join-marching-band-302912922.html

SOURCE Eastern Michigan University

Continue Reading

Technology

Green Ammonia Market to Reach USD 5.10 Billion by 2035 as Renewable Hydrogen Contracts Support New Production

Published

on

By

LONDON, Oct. 19, 2026 /PRNewswire/ — The global green ammonia market was valued at USD 150.8 million in 2025 and is projected to reach USD 5.10 billion by 2035, according to Credence Research. The report states a 42.22% compound annual growth rate for 2025-2035. Asia Pacific held the largest regional share at 60.2% in 2025, while Latin America is the fastest-growing region at a modeled 54.11% annual rate. Market sizes, segment shares and regional allocations are Credence Research estimates.

Key Takeaways

Credence Research estimates market value at USD 150.8 million in 2025 and USD 5.10 billion by 2035, with a reported 42.22% CAGR for 2025-2035.Asia Pacific held 60.2% of modeled 2025 value. Latin America has the fastest forecast regional growth at 54.11%.Alkaline water electrolysis represented 73.6% of 2025 technology value.Fertilizers accounted for 68.3% of 2025 application revenue, the largest end use.Solid oxide electrolysis has the highest modeled technology growth at 63.37% annually, from a small base.Marine fuel is projected to grow fastest among applications, but its starting commercial base remains limited.

Scope & Segmentation – Green Ammonia Market

The market measures the selling value of ammonia made with electrolytic hydrogen powered by renewable electricity, including relevant renewable output from retrofitted fertilizer plants. It covers fertilizer, chemical feedstock, power and prospective marine fuel uses. It excludes conventional ammonia, blue ammonia made with fossil hydrogen and carbon capture, stand-alone electrolyzers, renewable generation equipment and downstream fertilizer products beyond the contained ammonia value.

By technology: Alkaline water electrolysis; Proton exchange membrane electrolysis; Solid oxide electrolysis.By application: Fertilizers; Industrial and chemical feedstock; Power generation; Marine fuel; Other uses including hydrogen carriers and refrigeration.

Read the full report and request a sample: https://www.credenceresearch.com/report/green-ammonia-market      

Why This Report Matters

Developers can separate announced electrolyzer capacity from renewable ammonia that has a committed buyer and a credible delivery schedule.Fertilizer companies and importers can evaluate the commercial importance of certification, fixed-price contracts and renewable electricity availability.Investors can assess why some projects advance with binding offtake while others remain exposed to cost gaps, policy changes and financing delays.

Market Overview

Green ammonia is produced using hydrogen generated from water electrolysis powered by renewable electricity, followed by conventional ammonia synthesis. It can serve fertilizer and chemical demand without changing the basic molecule, but production costs and emissions depend on the power supply and plant operation.

Early commercial output is concentrated in China and a small number of European plants. Indian supply contracts and international offtake agreements are expanding the project pipeline. Marine fuel is a longer-term opportunity, with demand dependent on vessel technology, bunkering infrastructure and shipping regulation.

Market Insights

Alkaline water electrolysis represented 73.6% of 2025 technology value.Fertilizers accounted for 68.3% of 2025 application revenue, the largest end use.Solid oxide electrolysis has the highest modeled technology growth at 63.37% annually, from a small base.Marine fuel is projected to grow fastest among applications, but its starting commercial base remains limited.Asia Pacific represented 60.2% of 2025 value, reflecting early Chinese plant output and demand.

Key Attributes

Attribute

Details

Historical reference

2018-2025 (source report)

Base year

2025

Market size, 2025

USD 150.8 million

Market size, 2026 (source estimate)

USD 415.2 million

Market size, 2035

USD 5.10 billion

Reported CAGR and measurement interval

42.22% (2025-2035)

Largest regional share

Asia Pacific (60.2%, 2025)

Fastest-growing region

Latin America (54.11%)

Segments covered

Technology, Application

Geographic coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Market Segmentation

The segmentation below follows the current report taxonomy and separates products, applications and buyers to avoid overlapping revenue definitions.

By technology: Alkaline water electrolysis; Proton exchange membrane electrolysis; Solid oxide electrolysis.By application: Fertilizers; Industrial and chemical feedstock; Power generation; Marine fuel; Other uses including hydrogen carriers and refrigeration.

Market Drivers

Fertilizer producers can reduce reliance on fossil-based hydrogen by purchasing certified renewable ammonia or replacing a portion of their own feedstock. Long-term supply contracts can make the economics more predictable for producers and buyers.

Large renewable energy resources and improving electrolyzer supply support new plants in China, India and prospective export hubs. Project economics still depend heavily on utilization and electricity costs.

Cross-border contracts create a clearer financing route than nonbinding project announcements. Importers that require renewable fuel certification can anchor investments in production and shipping logistics.

Regional Analysis

The following regional shares represent Credence Research estimates of 2025 market value. They are not independently audited supplier sales totals.

Asia Pacific | 60.2% share in 2025

Operating Chinese plants and Indian fertilizer procurement programs underpin the largest base. Japan and South Korea are potential import markets for certified supply.

Europe | 26.7% share in 2025

Pioneer projects and stringent certification requirements support premium demand, while high energy costs encourage some buyers to seek imports.

Middle East and Africa | 8.0% share in 2025

Saudi Arabian and other coastal projects seek to pair renewable power with export infrastructure, but project schedules remain important.

North America | 3.3% share in 2025

Electrolytic ammonia remains a small share of supply, with some producers favoring carbon capture on conventional plants.

Latin America | 1.8% share in 2025

Chile and Brazil have strong renewable resources and potential fertilizer or export demand, producing the fastest modeled regional growth from a small base.

Market Challenges

Renewable ammonia generally costs more to produce than conventional ammonia. Intermittent wind and solar power complicate operation of the synthesis loop and can require storage or grid balancing.

Many proposed projects lack binding buyers, permitting or funding. Uncertain global shipping rules can delay marine-fuel demand, so developers often prioritize fertilizer and chemical customers first.

Future Outlook

The strongest near-term projects are likely to be those with verified renewable electricity, certification and binding offtake. China remains an early production center while India and Gulf projects could expand exports later in the decade.

Marine fuel demand may eventually diversify the customer base, but the timeline is uncertain. Investors should distinguish operating tonnage from proposed capacity and account for power variability, shipping costs and policy risk.

Competitive Landscape

Envision Energy, State Power Investment Corporation and China Energy Engineering are linked to operating Chinese renewable ammonia projects. AM Green, ACME Group and NEOM Green Hydrogen Company are export developers, while Yara and Iberdrola participate in European pioneer projects. Air Products is a NEOM co-owner and contracted offtaker, not simply an independent ammonia producer. Fortescue is excluded from the active producer list because it canceled selected hydrogen projects in 2025. No reliable comparable company-by-company green ammonia revenue ranking is available.

Key Players

Envision EnergyState Power Investment CorporationChina Energy EngineeringAM GreenACME GroupNEOM Green Hydrogen CompanyYara InternationalIberdrolaAir Products (offtaker and co-owner)

Recent Developments

Feb. 27, 2026: Envision announced a commercial shipment of green ammonia from its Chifeng facility in China to LOTTE Fine Chemical in South Korea. The company described the cargo as an end-to-end renewable ammonia delivery.

Jan. 12, 2026: Uniper and AM Green signed a binding long-term agreement for up to 500,000 metric tons a year of certified renewable ammonia from India, with initial deliveries expected from 2028.

Report Coverage

The study analyzes market size, the base-year product and application mix, regional demand, technology adoption, competitive positioning, constraints and dated industry developments. It also examines commercialization, customer economics and the factors that could change the pace of adoption through 2035.

Forecasts and regional shares are proprietary Credence Research model estimates. Company announcements and regulatory materials are used for industry context; they do not independently validate the modeled global revenue totals. The report’s market definition and exclusions should be considered when comparing it with broader adjacent industries.

Read the full report and request a sample: https://www.credenceresearch.com/report/green-ammonia-market

Related Reports

Green Hydrogen MarketBlue Ammonia MarketRenewable Methanol MarketSustainable Aviation Fuel MarketHydrogen Storage Market

About Us

Credence Research Inc. is a global market intelligence and consulting firm founded in 2015. It provides quantitative market research, competitive intelligence and strategic advisory services to organizations assessing new products, investment decisions and regional opportunities. The firm combines primary and secondary research with industry interviews and structured market models.

Its research spans industrial technology, semiconductors, energy, health care, consumer markets and other sectors. Credence Research evaluates market size, segmentation, growth drivers, supply-chain risks, regional policy and competitive positioning to help clients make evidence-led decisions.

Contact Us

Credence Research Inc.
Tower C-1105, S 25, Akash Tower
Vishal Nagar, Pimple Nilakh, Haveli
Pune – 411027, India
Europe: +44 7453 598 606 | North America: +1 6282 627 656
Email: sales@credenceresearch.com

Website: Credence Research

 

View original content:https://www.prnewswire.co.uk/news-releases/green-ammonia-market-to-reach-usd-5-10-billion-by-2035-as-renewable-hydrogen-contracts-support-new-production-302912925.html

Continue Reading

Trending